Andes Biotechnologies announces that the Board has accepted Dr. Arturo Yudelevich’s resignation as director of the Company. The Board appreciates the time and commitment Dr. Yudelevich has devoted to our company in all these years. We wish him well in his future business and personal ventures.
Filling the position to be vacated by Dr. Yudelevich, the Company also announces the appointment of Dr. Ahmed M. Hamdy as an Independent Board Member and Clinical Advisor. Dr. Hamdy brings over twenty years of Clinical Development, Clinical Operations and Medical Affairs experience to Andes Biotechnologies’ board.
Dr. Ahmed Hamdy is a founder of Acerta Pharma, a member of the AstraZeneca Group, and has previously served as Chief Executive Officer and in multiple Chief Medical Officer roles across the Pharmaceutical Industry.
To access Dr. Hamdy’s profile, click in the following link: http://andesbio.com/ahmed-hamdy/